Status:
COMPLETED
Medical Treatment of "High-Risk" Neurofibromas
Lead Sponsor:
Corewell Health West
Conditions:
Neurofibromatosis 1
Eligibility:
All Genders
2-30 years
Phase:
PHASE2
Brief Summary
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical ...
Detailed Description
The study's design involves treating eligible patients with a combination of celecoxib and pegylated interferon alpha-2b. If the patients have at least a partial response after six months, they may co...
Eligibility Criteria
Inclusion
- "High-Risk" Plexiform Neurofibromas associated with a diagnosis of NF1
- 2-30 years old (minimum bodyweight of 10 kilograms)
- Adequate renal function
Exclusion
- Previously untreated active optic glioma
- History of any previous allergy to study medications
- History of ischemic vascular disease
- Pregnancy / Breast feeding
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00846430
Start Date
October 1 2008
End Date
May 1 2017
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States, 49503